Studies how treatments and patient factors affect thyroid cancer outcomes
Observes how treatments and clinical features influence outcomes in people with thyroid cancer.
Plain-language title generated from the registry record
Registry title: Impact of Conventional Treatments and Clinical Variables on Thyroid Cancer
Key facts
- Where
- Milan, ItalySee the site
Where in Italy
- Istituto Auxologico Italiano IRCCSMilan, ItalyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Istituto Auxologico Italiano
- Trial code
- NCT05752604
- Record updated
- 3 August 2025
- Original description
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.Read full original descriptionShow less
Retrospective and Prospective Evaluation of the Impact of Innovative and Conventional Treatments and of Clinical Variables on the Outcome of Thyroid Cancer
DTC has a generally favorable prognosis. The possibility to discriminate between patients with aggressive tumors and those with a more indolent behavior may reduce the need for unnecessary treatments. Aim of this observational study is to evaluate how anamnestic, clinical, and histopathological variables may influence the outcome of the enrolled patients, both regarding morbidity and mortality and in terms of therapeutic choices. The study aims to evaluate the prognostic impact of the therapeutic interventions in terms of efficacy and regarding the appearance of adverse events.
Inclusion: thyroid cancer diagnosis.
Exclusion: patients unable to sign informed consent.